secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-04-08T23:59:59+00:00
Accession:  0001104659-24-044750
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics appoints Gene Mack as CFO effective April 8, 2024
-------------------------------------------------------------------

- Gene Mack appointed CFO; previously CFO at Imcyse SA and OncoC4; over 25 years in life sciences.
- Annual base salary $370,000; target cash bonus of 35% of base salary.
- Inducement option to purchase 200,000 shares at $3.56, vesting over 4 years with 25% on first anniversary.
- Gianluca Fuggetta steps down as principal financial officer but remains VP of Finance and principal accounting officer.
- Mack also appointed as Secretary of the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924044750/0001104659-24-044750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924044750/tm2411246d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-044750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer